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The research of neurological diseases has great importance and the determination of 
neurotransmitter concentrations is essential during these investigations. The levels of main 
excitatory (glutamate) and inhibitory (γ-amino-butyric acid (GABA)) neurotransmitters often 
change as a result of pathological alterations. For example, in case of migraine, elevated 
glutamate release is suggested to be a part of the pathomechanism, causing hypersensitivity to 
pain. Our goal in this study was to optimize a liquid chromatography method to measure 
glutamate and GABA from the trigeminal nucleus pars caudalis (TNC) of rats, which is 
responsible for pain processing. As a result, we were able to validate our method according to 
international guidelines where the investigated parameters were LOD, LOQ, precision and 
recovery. Furthermore, we applied a new internal standard which has not been published so 
far. This method will be utilized in the investigation of migraine animal models to evaluate 
potential new therapeutic approaches. 
 
Introduction 
Headache, one of the most common disorders of the nervous system, is a major health 
problem worldwide. The global prevalence of active headache disorders for the adult 
population is 46% for headache in general, 11% for migraine, 42% for tension-type headache 
and 3% for chronic daily headache [1]. The treatment of primary headache disorders is 
challenging and requires both acute and preventive therapeutic strategies [2]. The efficacy of 
these treatments is not always satisfactory and the contraindications and side-effects often 
limit the options of the physician [3, 4]. There is, therefore, a constant need for the study and 
development of new therapeutic approaches. 
Animal and human studies suggest that glutamate receptors are present in various parts of the 
trigeminal system [5] which is the system responsible for processing most of the pain 
originating from the head area [6]. The stimulation of the trigeminal nerve results in elevated 
glutamate levels in the spinal trigeminal nucleus pars caudalis (TNC, [7]). The peripheral 
application of glutamate to deep craniofacial tissue proved to activate and sensitize 
nociceptive afferents and neurons in the upper cervical cord [8]. These findings suggest that 
excitatory amino acid receptors (particularly N-methyl-D-aspartate receptors (NMDAR)) play 
an important role in pain processing and the sensitization process as well [9]. 
Based on these findings, our aim in this study was to optimize an HPLC method to measure 
the excitatory amino acid glutamate and its inhibitory counterpart γ-amino-butyric acid 
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(GABA) in rat TNC samples for the future evaluation of these neurotransmitters in preclinical 
investigations of migraine. 
 
Sample acquisition and preparation 
For this study we used male Sprague-Dawley rats weighing 250-300 g. The animals were 
housed in cages under standard conditions with a 12-12-h light-dark cycle and free access to 
food and water. To acquire the TNC, rats were anesthetized with 4 w/w% chloral hydrate 
intraperitoneally then they were transcardially perfused with artificial cerebrospinal fluid (pH 
= 7.4, concentrations in mM: 122 NaCl, 3 KCl, 1 Na2SO4, 1,25 KH2PO4, 10 D-glucose 
monohydrate, 1 MgCl2 x 6 H2O, 2 CaCl2 x 2 H2O, 6 NaHCO3). The samples containing the 
medullary segment of TNC were then removed and stored at -80°C until measurement. 
Before measurement, the tissue samples were sonicated in ice cold 85% methanol (10 µl/mg 
tissue) then they were centrifuged (12 000 RPM, 10 min, 4°C) and the supernatants were 
collected. Then 100 µl sample was derivatized with 100 µl freshly prepared solution (2 ml o-
phthaldialdehyde, 7.94 ml 0.2 M borate puffer (pH = 9.9), 60 µl 3-mercaptopropionic acid) 
and 50 µl distilled water containing the internal standards homoserine and (1R,2S)‐2-amino 
cyclopent‐3‐ene‐1‐carboxylic acid (ACK). 
 
HPLC method 
For the determination of glutamate and GABA, we used an Agilent 1100/1260 system 
(Agilent Technologies, Santa Clara, CA, USA) equipped with a fluorescence detector (FLD). 
Chromatographic separations were performed on a Kinetex C18 150x4.6 i.d. 5 µm particle 
size column (Phenomenex Inc., Torrance, CA, USA) after passage through a SecurityGuard 
pre-column C18, 4x3 mm i.d., 5 µm particle size (Phenomenex Inc., Torrance, CA, USA) 
applying gradient elution. Mobile phase A was 95:5 V/V% 0.05 M sodium acetate (pH = 
5.5):methanol, while mobile phase B was 45:45:10 V/V% methanol:acetonitrile:water. The 
elution started with 95% A decreasing linearly to 50% then staying there for 2 min and 
reequilibrating to 95% in 1 min for a total 16 min runtime. The flow rate was 1 ml/min, 
injection volume was 10 µl and the fluorescent detector was set to 230/440 nm for 
excitation/emission wavelengths. 
 
Results and discussion 
The first step of our method optimization was to determine the optimal excitation and 
emission wavelengths for the fluorescent detector. The acquired spectrum can be seen in 




Figure 1. The fluorescent spectum of glutamate 
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Figure 2. The fluorescent spectrum of GABA 
 
During our measurements we used standard solutions in 6 different concentrations for 
external calibration. The calculated calibration curve was linear in the investigated 
concentration range and its details can be seen in Table 1. 
 
Table 1. Main characteristics of calibration 
 Glu GABA Homoserine ACK 
Calibration range (G/ML) 0.08–4 0.008–0.4 0.4 0.4 
Calibration line slope 0.591 3.581 - - 
Calibration line  0.0013 0.0081 - - 
Intercept linearity (R
2
) 0.999 0.999 - - 
Retention time (min) 5.348 10.713 7.036 12.627 
 
The selectivity of the method was checked by comparing the chromatograms of glutamate, 
GABA, homoserine and ACK for a blank TNC sample and those for a spiked sample. All 
compounds could be detected in their own selected chromatograms without any significant 
interference. A sample chromatogram of a TNC sample can be seen on Figure 3. 
  
 




Figure 3. Representative chromatogram of a TNC sample with (red) and without (blue) 
internal standards. Glu glutamate; HS homoserine; GABA γ-amino-butyric acid; ACK 
(1R,2S)‐2-amino cyclopent‐3‐ene‐1‐carboxylic acid 
 
In the current study, LOD and LOQ were calculated as shown in Equation 1. The LOD values 
for glutamate and GABA were 0.03 and 0.006 g/ml, respectively. The LOQ values for 
glutamate and GABA were 0.09 és 0.019 g/ml, respectively 
 
LOD = 3.3 ∗
Df
S′ 
 and LOQ = 10 ∗
Df
S′ 
   
Equation 1. 
The calculation of LOD and LOQ values by formula, where σ is the standard error of the 
intercept and S’ is the slope of the calibration curve of the analyte. LOD limit of detection; 
LOQ limit of quantification. 
 
With regard to the within-run precision, after 6 consecutive injections the coefficients of 
variation of the concentrations were 1.3% and 0.35% for glutamate and GABA, respectively. 
The relative recoveries were estimated by measuring spiked samples of glutamate and GABA 
at two different concentration levels with three replicates of each. No significant differences 
were observed for the lower and higher concentrations. The recoveries for the TNC samples 
ranged from 88 to 100% for glutamate and 104 to 122% for GABA. These results are in line 
with Food and Drug Administration recommendations [10]. 
 
Conclusion 
As a result of our method optimization, we were able to measure glutamate and GABA from 
rat TNC samples with a robust, reliable method. This region of the central nervous system 
was not investigated before with similar applications. Furthermore, we also applied a new 
internal standard for amino acid determination, which was not described before. In the future, 
this method will be applied in animal models of migraine to investigate potential protective 
therapies and we plan to extend this method to other biological matrices too, especially for 
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